Schedule 13G/A

MNLOUSD Schedule 13G/A filing by Citadel Advisors

Citadel Advisors reported beneficial ownership of 3.7K shares, representing 0% of VYNE THERAPEUTICS INC in this filing.

FiledNov 14, 2025

Ownership dateSep 30, 2025

Reported shares3.7K

Reported ownership0%

Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0

Shared voting power 3.7K

Sole dispositive power 0

Shared dispositive power 3.7K

Compared with the prior filing

How the reported position changed

This compares the current filing with the previous tracked Schedule 13 filing from the same reporting CIK for MNLOUSD. A change between filings does not by itself establish when shares were bought or sold.

Previous filingMay 15, 2025

Reported share change-1,096,597

Ownership percentage change-7.2 pts

	Previous filing	This filing
Reported shares	1.1M	3.7K
Reported ownership	7.2%	0%

Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer: Citadel Advisors
CIK: CIK0001423053
Accession: 0001104659-25-112496
Form: Schedule 13G/A

Open SEC filing View MNLOUSD ownership history

Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →